--- title: Research into the comorbidities of obesity description: Obesity contributes to many comorbid conditions. Research into these comorbidities means studying a whole range of complex interactions. --- [![profil-logo-wortbild-with claim-4c-offset_1000px](https://www.profil.com/hs-fs/hubfs/profil-logo-wortbild-with%20claim-4c-offset_1000px.png?width=250&name=profil-logo-wortbild-with%20claim-4c-offset_1000px.png "profil-logo-wortbild-with claim-4c-offset_1000px")](https://www.profil.com?hsLang=en-us) [![Contact](https://no-cache.hubspot.com/cta/default/481167/1f89c7d1-107f-4c8d-aa7b-f85d0dce14da.png)](https://cta-redirect.hubspot.com/cta/redirect/481167/1f89c7d1-107f-4c8d-aa7b-f85d0dce14da) [Patient information](https://www.profil.de) # [![Obesity Treatment Header](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/Header/Header_1077x260px_Obesity_Treatment.jpg?width=1077&height=260&name=Header_1077x260px_Obesity_Treatment.jpg) Obesity Comorbidities Learn about the comorbidities associated with obesity.](https://www.profil.com/expertise/comorbidities#) ## The comorbidities of obesity Obesity contributes to numerous comorbid conditions. Obese patients are at increased risk of developing many medical problems, including insulin resistance, type 2 diabetes mellitus, hypertension, dyslipidemia, cardiovascular disease, stroke, sleep apnea, gall bladder disease, hyperuricemia, gout, osteoarthritis and even certain cancers. Current obesity comorbidity research has several important lines of investigation. The proportional importance of subcutaneous versus visceral fat in producing comorbidities and the impact of adipose tissue inflammation are significant topics. It is also important to elucidate the independent contributions of diet and sedentariness to the development of each of the comorbidities. Furthermore, the impact of gender, race and duration of a given state must be clarified. Obesity and its comorbidities have complex interactions and multiple influencing factors. Performing any obesity comorbidity study requires in-depth knowledge of metabolic conditions, obesity and clinical trials. ![Icon_NewWebinar](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_NewWebinar.png?width=62&height=70&name=Icon_NewWebinar.png) ### Online Seminar On-demand Online Seminar: **"Early phase obesity research & ** **how to measure outcomes ** **of interest****"**   [![Watch now](https://no-cache.hubspot.com/cta/default/481167/52ba76b5-3c5a-417b-b1fb-0ca6fa2448e5.png)](https://cta-redirect.hubspot.com/cta/redirect/481167/52ba76b5-3c5a-417b-b1fb-0ca6fa2448e5) ![Leona_Hexagon_neu](https://www.profil.com/hs-fs/hubfs/Leona_Hexagon_neu.png?width=154&height=175&name=Leona_Hexagon_neu.png) ### Our expert **Prof. Dr. Leona Plum-Mörschel** Chief Executive Officer [![Contact](https://no-cache.hubspot.com/cta/default/481167/7d2be928-2810-4791-b064-71c6e16cb1b8.png)](https://cta-redirect.hubspot.com/cta/redirect/481167/7d2be928-2810-4791-b064-71c6e16cb1b8) ![blank.jpg](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_References.png?width=49&height=49&name=Icon_References.png) #### References We have published with the following sponsors: ![Referenzen](https://www.profil.com/hubfs/BLUE_MOON/content-bilder/Referenzen.gif "Referenzen") [View more](https://www.profil.com/knowledge-center/references?hsLang=en-us) ![blank.jpg](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_Certificates.png?width=44&height=49&name=Icon_Certificates.png) #### Certificates | ![13485_Zertifikatssiegel_black_A3](https://www.profil.com/hubfs/BLUE_MOON/piktos/ISO_134852016_certificate_blue.png) ISO 13485:2016 ![27001_Zertifikatssiegel](https://www.profil.com/hubfs/BLUE_MOON/piktos/ISO_27001_certificate_.png) ISO 27001 | ![9001:2015_Zertifikatssiegel](https://www.profil.com/hubfs/BLUE_MOON/piktos/ISO_9001-2015_certificate.png) ISO 9001:2015 ![9001:2015_Zertifikatssiegel](https://www.profil.com/hubfs/BLUE_MOON/piktos/BVMA_Logo_Certificate_size.png) BVMA Member | | --- | --- | ![blank.jpg](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_Publications.png?width=44&height=49&name=Icon_Publications.png) #### Publications Ambery, P. et al. 2018. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018 Jun 30;391(10140):2607-2618. [View all](https://www.profil.com/knowledge-center/publications?hsLang=en-us) Thanks to its Obesity & Prediabetes Department, which has its own metabolic ward, the Profil Institute for Metabolic Research can support a range of obesity comorbidity research. ###### Profil Institut für Stoffwechselforschung GmbH Hellersbergstraße 9 · 41460 - Neuss, Germany Telefon +49-2131-4018-345 · marketing@profil.com [Imprint](https://www.profil.com/imprint?hsLang=en-us) | [Privacy Policy](https://www.profil.com/privacy?hsLang=en-us)